← Back to Search

Advanced MRI Techniques for Li-Fraumeni Syndrome

N/A

Waitlist Available

Led By Andrea Doria, MD

Research Sponsored by The Hospital for Sick Children

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

LFS kindreds who either carry a known TP53 mutation or are obligate mutation carriers

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 2 years

Awards & highlights

No Placebo-Only Group

Summary

This trial will use new techniques to MRI to see how well it can detect small tumors, and if it can tell the difference between cancerous and non-cancerous tumors.

Who is the study for?

This trial is for individuals with Li-Fraumeni Syndrome (LFS), a condition that greatly increases cancer risk. Participants must either carry a known TP53 mutation or be direct relatives of mutation carriers. They cannot take part if they have metal implants, pacemakers, or severe claustrophobia due to the MRI requirements.

What is being tested?

The study is testing advanced MRI techniques including PET-MRI, Whole body STIR MRI, and DW-MRI to detect small tumors in LFS patients. It aims to determine how effective these methods are at identifying malignant versus benign tumors.

What are the potential side effects?

There are generally no side effects associated with undergoing MRIs as they do not use ionizing radiation; however, some individuals may experience discomfort from lying still or anxiety due to the enclosed space.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My family has a known TP53 mutation, and I might carry it too.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Evaluation of imaging traits on suspected tumors

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: MRI ImagingExperimental Treatment3 Interventions

Participants will be imaged with the standard MRI technique (STIR-MRI) and also new MRI techniques called "diffusion weighted" or "DW" MRI and Positron Emission Tomography (PET)-MRI. PET-MRI will be indicated if the results from the routine MRI and DW MRI are contradictory or if laboratory results do not correspond to the standard MRI and DW MRI results.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PET-MRI

2018

N/A

~100

DW-MRI

2008

N/A

~50